Zydus Lifesciences Limited (ZYDUSLIFE) partners with Apollo Hospitals to expand access to Shield™ Multi-Cancer Detection test in India.
Zydus Lifesciences Limited (ZYDUSLIFE) completes acquisition of Assertio Holdings, acquiring 66.32% of shares at $23.50 per share.
Zydus Lifesciences Limited (ZYDUSLIFE) receives US FDA Priority Review for Saroglitazar NDA to treat Primary Biliary Cholangitis (PBC).
Zydus Lifesciences Limited (ZYDUSLIFE) reports a 16% YoY revenue growth for Q4 FY26, with EBITDA margin improving to 33.7%.
USFDA inspection concludes at Zydus Lifesciences Limited's Biologics Injectable plant in Ahmedabad with seven observations.